» Articles » PMID: 37492709

Identification of New Aptamer BC-3 Targeting RPS7 from Rapid Screening for Bladder Carcinoma

Overview
Journal Genes Dis
Date 2023 Jul 26
PMID 37492709
Authors
Affiliations
Soon will be listed here.
Abstract

Aptamers, short single DNA or RNA oligonucleotides, have shown immense application potential as molecular probes for the early diagnosis and therapy of cancer. However, conventional cell-SELEX technologies for aptamer discovery are time-consuming and laborious. Here we discovered a new aptamer BC-3 by using an improved rapid X-Aptamer selection process for human bladder carcinoma, for which there is no specific molecular probe yet. We show that BC-3 exhibited excellent affinity in bladder cancer cells but not normal cells. We demonstrate that BC-3 displayed high selectivity for tumor cells over their normal counterparts , in mice, and in patient tumor tissue specimens. Further endocytosis pathway analysis revealed that BC-3 internalized into bladder cancer cells via clathrin-mediated endocytosis. Importantly, we identified ribosomal protein S7 (RPS7) as the binding target of BC-3 via an integrated methodology (mass spectrometry, colocalization assay, and immunoblotting). Together, we report that a novel aptamer BC-3 is discovered for bladder cancer and its properties in the disease are unearthed. Our findings will facilitate the discovery of novel diagnostic and therapeutic strategies for bladder cancer.

Citing Articles

Identification and validation of basement membrane-related genes predicting prognosis and immune infiltration associated with bladder cancer.

Lai F, He L, Lia T, Yang Z, Huang C Medicine (Baltimore). 2024; 103(29):e38858.

PMID: 39029072 PMC: 11398827. DOI: 10.1097/MD.0000000000038858.


Targeting Prolyl 4-Hydroxylase Subunit Beta (P4HB) in Cancer: New Roads to Travel.

Feng D, Wang J, Li D, Wu R, Tuo Z, Yu Q Aging Dis. 2023; 15(6):2369-2380.

PMID: 38029391 PMC: 11567247. DOI: 10.14336/AD.2023.1126.


Molecularly imprinted polymers (MIPs): emerging biomaterials for cancer theragnostic applications.

Kang M, Cho E, Choi H, Amri C, Lee J, Kim K Biomater Res. 2023; 27(1):45.

PMID: 37173721 PMC: 10182667. DOI: 10.1186/s40824-023-00388-5.

References
1.
Lu E, Elizondo-Riojas M, Chang J, Volk D . Aptaligner: automated software for aligning pseudorandom DNA X-aptamers from next-generation sequencing data. Biochemistry. 2014; 53(22):3523-5. PMC: 4059528. DOI: 10.1021/bi500443e. View

2.
Zhou G, Latchoumanin O, Hebbard L, Duan W, Liddle C, George J . Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. Adv Drug Deliv Rev. 2018; 134:107-121. DOI: 10.1016/j.addr.2018.04.005. View

3.
Wu L, Kou F, Ji Z, Li B, Zhang B, Guo Y . SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7. Cell Death Dis. 2021; 12(5):439. PMC: 8089105. DOI: 10.1038/s41419-021-03720-w. View

4.
Zadeh J, Steenberg C, Bois J, Wolfe B, Pierce M, Khan A . NUPACK: Analysis and design of nucleic acid systems. J Comput Chem. 2010; 32(1):170-3. DOI: 10.1002/jcc.21596. View

5.
Wu X, Liu H, Han D, Peng B, Zhang H, Zhang L . Elucidation and Structural Modeling of CD71 as a Molecular Target for Cell-Specific Aptamer Binding. J Am Chem Soc. 2019; 141(27):10760-10769. PMC: 6625514. DOI: 10.1021/jacs.9b03720. View